

1996-2013 Medline (Pubmed version), Embase (Dialog version) Cochrane Library databases, : Guideline AASLD 2008 (American Association for the Study of Liver Diseases) Guideline EASL 2011 (European Association for the Study of the Liver).

10:

83.0

15

(3402delC), 13 (R969Q), , 8 (2299insC, G710S), ,  
 10%. 1069Q  
 30,5%, 3402delC – 2,2%. 30%  
 3402delC, - 2333G>T (R778L) 8 ,  
 12-45,6%

7 .

ATP7B – – ( – – 7 , – – 2, – – – ).

7

, , , , , , , , , , , , , ,

( .1).

	( )	( 100 )	1.
,	100		
23,9		0,170	
13,5		0,170	
7,5		0,150	
6,6		0,150	
5,0		0,140	
-	3,9	0,140	
	2,9	0,135	
	2,3	0,135	
	2,1	0,130	
	1,9	0,130	
	1,8	0,130	
	1,8	0,125	
	1,6	0,120	
	1,5	0,120	
	1,5	0,120	
	1,4	0,110	
	1,3	0,110	
	1,3	0,100	
	1,2	0,100	
	1,0	0,100	
	1,0	0,100	
	1,0	0,092	
	0,8	0,087	
	0,8	0,085	
	0,75	0,080	
	0,7	0,080	
	0,7	0,075	
	0,66	0,070	
	0,64	0,070	
	0,560	0,070	
	0,450	0,067	

	0,290		0,060
	0,240		0,047

- 2-4

- 5 -

).

(1 /


),

200 /

- 7

7

,  
 (-, 1).



. 1.

( . 2)

5-

2-

5

26%.

4

- 2 .

,

, ,

,

,

,

,

(44%)

(

),

,

( .2-4).

,

- ,

,

, ,


,

,

,

, , ,


( , , , , )



.2.

14


(  
400):



.3.

14

(  
100):



.4.

9


(  
400):

10%

2 1 (.2)

7-17%

10%




.5.

-2

11

» ( .3).



14 : - ( )  
14 : . 6. « » 14 « »

10%.

1-12%

	<ul style="list-style-type: none"> <li>•</li> </ul>	( )
	<ul style="list-style-type: none"> <li>•</li> </ul>	,
	<ul style="list-style-type: none"> <li>•</li> </ul>	
	<ul style="list-style-type: none"> <li>•</li> </ul>	:
		-
		, « »
		:
		,
		:
		,
		,
		,
		,
		,

( 83.0 - 10 ).

J.Walsh (1983):

(J.Walsh, 1983):

5 -

(1960),

2-3

(2-8

),

(10-15

);

20-30

). 6-8 (

1)  
2)

2 18

( 20 / );

✓  
✓

( 50 / );

(500

2

/ ) -

1600 /

250

/ (

);

;

(

);

• / 7 .  
**NB!** ( 7 ) ; 100% ; , .

VIII , (16 - 18 2001 , , )  
 ( . 3).

3.

I.		II.	
<u>1.</u> - _____	2 0	<u>1.</u> _____ - 1-2 - 2 - , 5	<b>0</b> <b>1</b> <b>2</b> <b>2</b>
<u>2.</u> _____ ( _____ ) - 250 / - 250 /	2 0	<u>2.</u> _____ - 50-250 / - 250 /	<b>-1</b> <b>1</b> <b>2</b>
<u>3.</u> - _____ - _____	1 0	<u>3.</u> - _____ ( _____ ) - -	<b>0</b> <b>1</b>
<b>III.</b> - ( - - )		<u>4.</u> ( _____ 20 / ) - 10-20 - 10	<b>0</b> <b>1</b> <b>2</b>

4 : ;

2-3: , ;

0-1: .

- ,

, ,

,

7 ( . 4).

4.

	(		)
	20	,	,


	/	,	,	,
		, 7 2	,	,
-		,	,	,
	50 /		,	,
-	1600 /		,	,
(500      2      )				
	250 /		,	,

,  
,

(  
,

,

),  
7 .



.7.  
; 24-h Cu -  
  
( ),  
, ,  
30 ,  
  
1  
1 3 ,  
2  
  
( , , , , ).  
,  
,  
,  
,  
,  
,  
,  
,  
,  
1 2 ,  
250 250-500 /  
1000-1500 / ( 4-7 ) 2-4  
20 / / .

30%  
30%  
25-30 %  
  
( , ,  
, ,  
( , ,  
,  
( , ,  
,  
6 ( )  
25-50 / .  
  
( , ,  
, ,  
( ,  
)  
  
:  
● ;  
● ;  
● ;  
● ,  
  
70%,  
95%, 5 - 83%, 10 - 80%.  
50% . ,  
2  
  
,  
6-9 ,

/

,

,

1-2

(Dhawan et al.),

11

5.

(**Dhawan et al.)**

	1	2	3	4
( / )	100-150	151-200	201-300	>300
( / )	100-150	151-300	301-400	>400
	1.3-1.6	1.7-1.9	2.0-2.4	>2.4
(10 <sup>9</sup> )	6.8-8.3	8.4-10.3	10.4-15.3	>15.3
/	34-44	25-33	21-24	<21

\*-

11